Clinical efficacy of ginkgo biloba extract combined with compound betamethasone injection for sudden sensorineural hearing loss
Objective To explore the efficacy of intravenous ginkgo biloba extract(GBE)combined with compound beta-methasone injection for the treatment of sudden sensorineural hearing loss(SSNHL)and its effects on patients'hearing lev-els and vascular endothelial growth factor(VEGF)signaling pathways,providing a reference for its clinical treatment.Methods A total of 86 SSNHL patients treated at the People's Hospital of Dazu,Chongqing from January 2021 to March 2023 were selected and randomly allocated to a control group and an observation group,with 43 cases each.Both groups re-ceived basic treatment;the control group was additionally treated with compound betamethasone injection behind the ear,while the observation group received GBE intravenous drip combined with the control group's treatment.The clinical effica-cy,pre-and post-treatment hearing levels,hemorheological indicators[plasma viscosity(PV),whole blood viscosity(WBV),hematocrit(HCT)],inner ear microcirculation indicators[soluble vascular cell adhesion molecule(sVCAM),en-dothelin(ET)],and VEGF signaling pathway indicators[VEGF,hypoxia-inducible factor-1α(HIF-1α)]were compared between the two groups,as well as the incidence of adverse reactions.Results The overall response rate in the observation group was significantly higher than that in the control group[93.02% (40/43)vs.76.74% (33/43);x2=4.440,P=0.035].Before treatment,there were no significant differences in hearing thresholds across frequency ranges between the two groups(P＞0.05);after 10 days of treatment,hearing thresholds in the high-frequency,low-frequency,and average thresholds were significantly lower in both groups compared to before treatment,with the observation group showing signif-icantly lower levels than the control group(P＜0.05).No significant differences were noted in PV,WBV,and HCT levels between the two groups before treatment(P＞0.05);after 10 days of treatment,these levels were significantly lower in both groups compared to before treatment,with the observation group being significantly lower than the control group(P＜0.05).Before treatment,no significant differences were observed in serum sVCAM and ET levels between the two groups(P＞0.05);after 10 days of treatment,these levels were significantly lower in both groups compared to before treatment,with the observation group being significantly lower than the control group(P＜0.05).Before treatment,no significant differences were found in serum VEGF and HIF-1α levels between the two groups(P＞0.05);after 10 days of treatment,these levels were significantly lower in both groups compared to before treatment,with the observation group being signifi-cantly lower than the control group(P＜0.05).The incidence of adverse reactions in the control and observation groups was 9.30% (4/43)and 11.63% (5/43),respectively,with no significant difference(x2=0.000,P=1.000).Conclusion In-travenous GBE combined with compound betamethasone injection for SSNHL can lower ET and sVCAM levels and effec-tively regulate inner ear hemorheological indicators through the activation of the HIF-1α-VEGF axis,thereby improving clin-ical symptoms and enhancing hearing levels.
万方数据
维普
